Friday, May 22, 2026 12:07:30 PM
Here's how Google AI describes them:
RoslinCT and Rose BioSolutions are both leading Contract Development and Manufacturing Organizations (CDMOs) specializing in the advanced cell and gene therapy sector. They provide the infrastructure and scientific expertise necessary to translate complex scientific research into clinical and commercial medicines.
Founded in 2006, RoslinCT (Roslin Cell Therapies) was spun out from the Roslin Institute in Scotland—the same institute famous for cloning Dolly the Sheep.
What they do: They provide process and analytical development, clinical and commercial manufacturing, and cell line development. They work with both autologous (a patient's own cells) and allogeneic (donor cells) platforms.
Notable Achievements: They played a pivotal role in manufacturing the world's first CRISPR-edited cell therapy (Casgevy / exa-cel) for sickle cell disease and beta-thalassemia.
Facilities: The company operates 22 purpose-built cleanroom suites across two primary hubs: Edinburgh, Scotland, and Hopkinton, Massachusetts.
Rose BioSolutions
Formed in May 2026, Rose BioSolutions (also known as Rose Bio) is an independent CDMO that was created when private equity firm GI Partners acquired the CDMO and Cell Solutions businesses from Charles River Laboratories.
What they do: Rose Bio provides end-to-end development and advanced manufacturing across plasmid DNA, viral vectors, and cell therapies. They also supply critical cellular materials required by researchers.
Facilities: The company operates several facilities across the globe, with locations in Rockville, Maryland; Memphis, Tennessee; Northridge, California; and Keele in the United Kingdom.
Details of their recent launch can be found in the BioSpace acquisition announcement.
And as you noted in your post, Rose BioSolutions originated from Cognate BioServices, our original manufacturer:
Before being acquired by Charles River and subsequently spun out into Rose BioSolutions, Cognate BioServices was a primary manufacturing partner for NWBO. The legacy leadership, tech-transfer templates, and structural knowledge of how to build an artisan dendritic cell pipeline survived these corporate transitions.
Thanks!
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
